Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some claims are broadly consistent with labeled indications and bleeding warning, but several statements are unsupported or incorrectly framed (notably diet-related warnings and kidney/liver disease risk; also adverse reactions framed as disease outcomes rather than trial-reported events).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription omega-3 fatty acid medication.
Label context: VASCEPA is icosapent ethyl; described in warnings as an EPA ethyl ester from fish oil.
Vascepa is designed to reduce triglyceride levels in the blood.
Indications and usage: adjunct to diet to reduce TG levels in severe hypertriglyceridemia; clinical pharmacology and studies report TG reduction vs placebo.
Vascepa can help prevent cardiovascular disease.
Indications and usage: adjunct to maximally tolerated statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization.
Vascepa has been shown to be effective in reducing triglyceride levels.
14.2 severe hypertriglyceridemia: reduced median TG relative to placebo; and clinical pharmacology notes TG reduction vs placebo.
Vascepa has been shown to improve cardiovascular outcomes in patients with high triglyceride levels.
14.1 REDUCE-IT: reduced risk for primary and key secondary composite endpoints in statin-treated patients with elevated TG levels.
Vascepa increases the risk of bleeding.
5.3 Bleeding: increased bleeding and serious bleeding vs placebo.
The risk of bleeding with Vascepa may be increased when Vascepa is combined with other medications that also increase the risk of bleeding.
5.3 Bleeding: incidence greater in patients receiving concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin).
It is not recommended to take Vascepa if you have a bleeding disorder.
Not supported as a labeled contraindication; however bleeding risk is discussed under warnings/precautions. (Marked as inaccurate/unsupported elsewhere; included here only because it is a paraphrase of risk framing, not a contraindication.)
Potential side effects of Vascepa include bleeding.
5.3 Bleeding describes bleeding events; also 6.1 lists atrial fibrillation among common adverse reactions, but the label explicitly characterizes bleeding as an associated risk.
Potential side effects of Vascepa include cardiovascular disease.
Not directly supported as an adverse reaction; only cardiovascular events reduction is described. (Marked as unsupported elsewhere.)
Potential side effects of Vascepa include kidney disease.
Not supported by supplied label excerpts.
Potential side effects of Vascepa include liver disease.
Not supported by supplied label excerpts.
Unsupported Statements
Combining Vascepa with high-fat diets may increase the risk of bleeding.
The provided label excerpts include no statement linking high-fat diets to increased bleeding risk.
Combining Vascepa with high-fat diets may increase the risk of cardiovascular disease.
The provided label excerpts do not discuss high-fat diet as a risk factor for cardiovascular disease in the context of Vascepa use.
Vascepa has been shown to increase the risk of kidney disease in some individuals.
No kidney disease risk is mentioned in the supplied label excerpts.
Combining Vascepa and high-fat diets may increase the risk of kidney disease.
No label support provided linking high-fat diets or Vascepa to kidney disease risk in the supplied excerpts.
Vascepa has been shown to increase the risk of liver disease, particularly in individuals with pre-existing liver disease.
No liver disease risk is mentioned in the supplied label excerpts.
Combining Vascepa and high-fat diets may increase the risk of liver disease.
No label support provided linking high-fat diets or Vascepa to liver disease risk in the supplied excerpts.
Individuals with pre-existing cardiovascular disease or bleeding disorders may be at particularly high risk when combining Vascepa with high-fat diets.
No label support for any 'high-fat diets' interaction with Vascepa or for this specific risk framing in the supplied excerpts.
It is not recommended to take Vascepa if you are already following a high-fat diet.
The provided label excerpts do not include such a dietary restriction/recommendation.
Potential side effects of Vascepa include cardiovascular disease.
The provided label excerpts indicate cardiovascular risk reduction (indications/clinical studies) rather than cardiovascular disease as an adverse reaction.
Potential side effects of Vascepa include kidney disease.
No kidney disease is listed as an adverse reaction in the supplied label excerpts.
Potential side effects of Vascepa include liver disease.
No liver disease is listed as an adverse reaction in the supplied label excerpts.
It is not recommended to take Vascepa if you have a bleeding disorder.
No contraindication or explicit 'not recommended' statement for bleeding disorders is present in the supplied label excerpts; only bleeding risk and monitoring are discussed.
Contradictions
Low
AI Statement
Potential side effects of Vascepa include cardiovascular disease.
Label Reference
Indications and usage: adjunct to statin to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization; 14.1 REDUCE-IT reduced cardiovascular event risk.
Important Omissions
Boxed warning: not evaluated because the provided label excerpts do not include any boxed warning section.
Importance:
Low
Atrial fibrillation/flutter risk (hospitalization) was not mentioned among the AI claims, despite being a labeled warning and a common adverse reaction.
Importance:
Moderate
Fish allergy potential is not mentioned in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Bleeding risk claim is supported, but multiple additional risk assertions (kidney/liver disease and high-fat diet-related risks) are unsupported by the supplied label excerpts, and one claim misframes cardiovascular disease as a side effect instead of an outcome risk reduction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several safety claims are not supported by the provided Vascepa label excerpts (kidney/liver disease; high-fat diet as a modifier; recommendation against use with high-fat diet/bleeding disorder as stated). Also one claim contradicts label direction regarding cardiovascular outcomes.
Suggested Improvement
Limit safety claims to labeled warnings/precautions and adverse reactions supported in the excerpts (e.g., bleeding, atrial fibrillation/flutter). Remove or rephrase unsupported diet-related, kidney, and liver disease risk statements unless directly supported by the complete label text not provided.